Actively Recruiting
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Led by Jonsson Comprehensive Cancer Center · Updated on 2025-08-12
30
Participants Needed
1
Research Sites
109 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.
CONDITIONS
Official Title
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspected or diagnosed adrenal, anal, bladder, brain, breast, cancer of unknown primary, cervical, cholangiocarcinoma, colorectal, esophageal, gastric, head and neck, hematologic, hepatocellular carcinoma, lung, medullary thyroid, neuroendocrine, ovarian, pancreatic, penile, peritoneal, pleural, prostate, sarcoma, salivary gland, solitary fibrous tumor, skin, testicular, thymus, thyroid, urothelial, uterus, or vaginal cancer
- Patients 18 years of age or older at the time of radiotracer administration
- Patients able to provide written informed consent
- Patients able to remain still for the imaging procedure lasting up to one hour
You will not qualify if you...
- Patients who are pregnant or nursing
- Patients with underlying diseases that might interfere with collecting high-quality data, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here